What HighlightLL Pharma does

HighlightLL Pharma (legal name: 杭州高光制药股份有限公司) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Hangzhou, China (Hangzhou Medical Port, Qiantang District). The company focuses on developing breakthrough small-molecule therapies for autoimmune and inflammatory diseases affecting both the peripheral and central nervous systems. It operates two distinct molecular platforms: a dual TYK2/JAK1 inhibitor platform, headlined by TLL-018 (吉诺昔替尼), the globally first peripheral-selective dual TYK2/JAK1 inhibitor currently in Phase III for chronic spontaneous urticaria and rheumatoid arthritis, and TLL-041 (BHV-8000), the globally first brain-penetrating TYK2/JAK1 inhibitor whose overseas rights were out-licensed to Biohaven in 2023 and which entered a global Phase II/III pivotal Parkinson's trial in May 2025; and an NLRP3 inflammasome inhibitor platform, with HL-400 (brain-penetrating, US Phase I completed April 2026) targeting neurodegenerative diseases and HL-450 targeting peripheral indications. Target patient populations include individuals with chronic spontaneous urticaria, rheumatoid arthritis, Parkinson's disease, and broader neurodegenerative conditions, where current therapies leave substantial unmet medical need.

The company's business model is that of a pre-revenue clinical-stage biopharma. Near-term monetization comes from licensing and co-development partnerships rather than direct product sales — most notably the 2023 Biohaven agreement for TLL-041 overseas rights — with future revenue expected from milestone payments, royalties, and eventually traditional pharmaceutical commercialization through prescription drug distribution channels upon regulatory approval. The go-to-market motion is therefore enterprise-style: partnership-driven global development for international assets and independent domestic development for the China-anchored pipeline. Headcount is small (11–50 employees), there is no commercial sales force, and pricing is not yet applicable to clinical-stage assets. Across two disclosed funding rounds (a ~$30.9M Series A in July 2021 led by AstraZeneca CICC Medical Industry Fund alongside Hankang Capital, Kaitai Capital, Yifeng Capital, and Zeyue Capital; and a ~$20.5M Series B in January 2025 led by Hankang Capital with Huajin Capital, Infinity Equity, and Kangjun Capital), the company has raised approximately $51.4M in total disclosed capital to fund late-stage clinical development and pipeline expansion.

Name

HighlightLL Pharma

Legal name

杭州高光制药股份有限公司

Website

https://highlightllpharma.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting peripheral and central nervous systems, with lead assets TLL-018 in Phase III and TLL-041 partnered with Biohaven.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Clinical-stage biopharmaceuticals
• TYK2/JAK1 inhibitors
• NLRP3 inhibitors
• Autoimmune disease therapeutics
• Inflammatory disease drugs

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-revenue clinical-stage biopharma. Revenue generation expected through licensing deals, co-development partnerships, and eventual product commercialization. The company has already secured an overseas licensing deal with Biohaven for TLL-041.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting the peripheral and central nervous systems. Its lead asset TLL-018 (ginnoxinib) is in Phase III trials for chronic spontaneous urticaria and rheumatoid arthritis, while TLL-041 (BHV-8000), a brain-penetrant TYK2/JAK1 inhibitor, has been out-licensed to Biohaven for Parkinson's disease. The company also operates an NLRP3 inhibitor platform with HL-400 (CNS) and HL-450 (peripheral).

Product overview

HighlightLL Pharma is a clinical-stage biopharma company developing breakthrough medicines for autoimmune/inflammatory diseases in peripheral and central nervous systems. The company operates two main platforms: a TYK2/JAK1 inhibitor platform (featuring TLL-018 for peripheral applications in CSU and RA, and TLL-041/BHV-8000 for brain-penetrating neurological applications) and an NLRP3 inhibitor platform (with HL-400 for neurodegenerative diseases and HL-450 for peripheral diseases). The TLL-018 and TLL-041 represent the world's first highly selective dual TYK2/JAK1 inhibitors, with TLL-041 being specifically designed for brain penetration.

Differentiator

Problem solved

Functional benefit

Products and services

• TLL-018 (ginnoxinib/吉诺昔替尼) The world's first peripheral-selective, highly selective dual TYK2/JAK1 inhibitor. Currently in Phase III clinical development for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA); intended as a prescription therapy for adult patients with these autoimmune/inflammatory conditions who have inadequate response to existing treatments.
• TLL-041 / BHV-8000 The world's first brain-penetrating TYK2/JAK1 inhibitor. Out-licensed to Biohaven in 2023 for overseas development and commercialization; being advanced by Biohaven in a global Phase II/III pivotal clinical trial for Parkinson's disease. Designed to address neuro-inflammation underlying CNS indications.
• HL-400 Brain-penetrating NLRP3 inflammasome inhibitor being developed for neurodegenerative diseases. US Phase I clinical trial completed; intended as a prescription therapy targeting neuroinflammation in CNS disorders.
• HL-450

Quantifiable outcome

• TLL-018 achieved positive topline data in rheumatoid arthritis Phase III clinical trial (April 2026)
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• BiohavenflagshipStrategic or Co-development Partner · 1 January 2023HighlightLL Pharma out-licensed overseas rights for TLL-041 (BHV-8000) to Biohaven in 2023. Biohaven advanced the brain-penetrating TYK2/JAK1 inhibitor to Parkinson's disease global Phase II/III pivotal clinical trial in May 2025. This represents a major strategic partnership for international development and commercialization of the company's brain-penetrating CNS asset.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Novartis: Novartis acquired IFM Tre to build an NLRP3 inhibitor pipeline, directly competing with HighlightLL's NLRP3 platform. As a broad incumbent, Novartis brings substantially greater scale and commercialization capability to the same mechanistic space.
• Roche: Roche acquired Inflazome in 2020 to access its NLRP3 inhibitor portfolio for inflammatory and CNS diseases. Roche represents a broad incumbent competitor to HighlightLL's NLRP3 franchise (HL-400, HL-450) in both neurodegenerative and peripheral indications.

Direct peers

• Incyte: Incyte is the originator of ruxolitinib (Jakavi, JAK1/2) and continues to develop next-generation JAK inhibitors. As a JAK-class pioneer, Incyte is a comparable peer in the autoimmune/inflammatory small-molecule space targeted by HighlightLL.
• AbbVie: AbbVie markets Rinvoq (upadacitinib), a JAK1 inhibitor approved across multiple autoimmune indications including RA and CSU-adjacent conditions. TLL-018 targets RA and CSU indications where Rinvoq is already an entrenched standard of care.
• Bristol-Myers Squibb: BMS developed and commercializes Sotyktu (deucravacitinib), an allosteric TYK2 inhibitor approved in psoriasis and advancing into other autoimmune indications. TLL-018 competes in the same autoimmune TYK2/JAK1 therapeutic space with overlapping patient populations.
• Pfizer: Pfizer markets Cibinqo (abrocitinib, JAK1) and Litfulo (ritlecitinib, JAK3/TEC) for atopic dermatitis and alopecia areata. Pfizer is also developing TYK2-targeting agents, directly overlapping HighlightLL's TYK2/JAK1 franchise in autoimmune diseases.
• Eli Lilly: Lilly markets Olumiant (baricitinib, JAK1/2) in collaboration with Incyte across RA, atopic dermatitis and alopecia areata. Lilly's JAK franchise directly competes with TLL-018 in RA and adjacent autoimmune indications.

Emerging players

• Kymera Therapeutics: Kymera is developing targeted protein degraders including a TYK2 degrader program for autoimmune diseases. Its TYK2 modality represents an emerging approach competing for the same autoimmune patient population targeted by TLL-018.
• NodThera: NodThera is a clinical-stage biotech developing brain-penetrant and peripheral NLRP3 inhibitors for inflammatory and neurodegenerative diseases. It is the closest direct emerging peer to HighlightLL's HL-400 (brain-penetrant NLRP3) and HL-450 programs.
• Olatec Therapeutics: Olatec is developing dapansutrile and other NLRP3 inhibitors for inflammatory and metabolic diseases. As an NLRP3-focused emerging player, Olatec competes with HighlightLL's NLRP3 platform in overlapping peripheral inflammatory indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HighlightLL Pharma